Treatment of essential hypertension with calcium channel blockers: What is the place of lercanidipine?

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 8, 2009, Pages 981-987

  Burnier, Michel ^a   Pruijm, Menno ^a   Wuerzner, Gregoire ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Dihydropyridines; Humans; Hypertension; Single pill combinations

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; ISRADIPINE; LACIDIPINE; LERCANIDIPINE; METOPROLOL; NICARDIPINE; NIFEDIPINE; NITRENDIPINE; RAMIPRIL; TELMISARTAN; UNCLASSIFIED DRUG; VALSARTAN;

ADD ON THERAPY; ANTIHYPERTENSIVE ACTIVITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE SEQUENCE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FLUSHING; GASTROINTESTINAL ABSORPTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HUMAN; HYPERTENSION; MONOTHERAPY; NONHUMAN; PERIPHERAL EDEMA; REFLEX TACHYCARDIA; REVIEW; SIDE EFFECT; STABLE ANGINA PECTORIS; TACHYCARDIA;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DRUG COMBINATIONS; ENALAPRIL; HUMANS; HYPERTENSION;

EID: 68149164609     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903085135     Document Type: Review

References (35)

1. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288:2981-2997
2. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031 (Pubitemid 38781102)
3. Dahlöf B, Severs PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366(9489):895-906 (Pubitemid 41265663)
4. Jamerson K, Weber MA, Bakris GL, et al: for the ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high risk patients. N Eng J Med 2008;359:2417-2428
5. Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med 1999;341:1447-1457
6. Herbette LG, Vecchiarelli M, Sartani A, Leonardi A. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular models to rationalize its pharmacokinetic properties. Blood Press Suppl 1998;2:10-17
7. Bang LM, Chapman TM, Goa KL. Lercanidipine: a review of its efficacy in the management of hypertension. Drugs 2003;63:2449-2472 (Pubitemid 37392913)
8. Sironi G, Montagna E, Greto L, et al. Haemodynamic effects of lercanidipine in anaesthetized open-chest dogs. Arzneimittelforschung 1996;46:256-261 (Pubitemid 26109479)
9. Cherubini A, Fabris F, Ferrari E, et al. Comparative effects of lercanidipine, lacidipine and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients : the ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr 2003;37:203-212 (Pubitemid 37162859)
10. Romito R, Pansini MI, Perticone F, et al. Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in Adults (LEAD) Study. J Clin Hypertens 2003;5:249-253 (Pubitemid 37098484)
11. Leonetti G, Magnani B, Pessina AC, et al.; COHORT Study Group. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002;15:932-940 (Pubitemid 35217397)
12. Barrios V, Navarro A, Esteras A, et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Press 2002;11:95-100 (Pubitemid 34537518)
13. Burnier M, Gasser UE. Efficacy and tolerability of lercanidipine in patients with hypertension: results of a Phase IV study in general practice. Expert Opin Pharmacother 2007;8(14):2215-2223 (Pubitemid 350001585)
14. Barrios V, Escobar C, de la Figuera M, et al. Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE study. Cardiovasc Ther 2008;26:2-9
15. Barrios V, Escobar C, Navarro A, et al: LAURA Investigators. Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. Int J Clin Pract 2006;60(11):1364-1370 (Pubitemid 44560332)
16. Borghi C. Lercanidipine in hypertension. Vasc Health Risk Manag 2005;1(3):173-182
17. Dalla Vestra M, Pozza G, Mosca A, et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study. Diabetes Nutr Metab 2004;17:259-266
18. Sasaki T, Maruyama H, Kase Y, et al. Antianginal effects of lercanidipine on the vasopressin or metacholine induced anginal models in rats. Biol Pharm Bull 2005;28(5):811-816 (Pubitemid 40740646)
19. Acanfora D, Gheorghiade M, Trojano L, et al. A randomized, double-blind comparison of lercanidipine 10 and 20mg in patients with stable effort angina: clinical evaluation of cardiac function by ambulatory ventricular scintigraphic monitoring. Am J Ther 2004;11(6):423-432
20. Borghi C, Prandin MG, Dormi A, Ambrosioni E. Study group of the regional Unit of the Italian Society of Hypertension. Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press 2003;(Suppl 1):14-21
21. Lund-Johansen P, Stranden E, Helberg S, et al. Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J Hypertens 2003;21:1003-1010 (Pubitemid 36677166)
22. Fogari R, Malamani GD, Zoppi A, et al. Comparative effect of lercanidipine and nifedipine Gastrointestinal Therapeutic System on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double-blind, randomized, parallel-group study. Curr Ther Res Clin Exp 2000;61:850-862 (Pubitemid 32015352)
23. Fogari R, Mugellini A, Zoppi A, et al. Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens 2003;16:1357-1369
24. Pedrinelli R, Dell'Omo G, Nuti M, et al. Heterogeneous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients. J Hypertens 2003;21(10):1969-1973 (Pubitemid 37290117)
25. Hollenberg NK. Observations on the safety of lercanidipine: adverse events from placebo-controlled trials. Am J Hypertens 2002;15:58A-9A
26. Burnier M, Brown RE, Ong SH, et al. Issues in blood pressure control and the potential role of single-pill combination therapies. Int J Clin Pract 2009;63(5):790-798
27. Quan A, Chavanu K, Merkel J. A review of the efficacy of fixeddose combinations of olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies. Am J Cardiovasc Drugs 2006;6:103-113
28. Stergiou G, Makris T, Papavasiliou M, et al. Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocking monotherapy. Hypertens 2005;23:883-889 (Pubitemid 40523289)
29. Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007;21:220-224 (Pubitemid 46267738)
30. Cleophas TJ, van Ouwekerk BM, van der Meulen J, et al. Diabetics with hypertension not controlled with ACE-inhibitors: alternate therapies. Angiology 2001;52(7):469-475
31. Grandi AM, Solbiati F, Laurita E, et al. Effects of dual blockade of renin-angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study. Am J Hypertens 2008;21(2):231-237 (Pubitemid 351231577)
32. Agrawal R, Marx A, Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens 2006;24(1):185-192 (Pubitemid 41818104)
33. Hair PI, Scott LJ, Perry CM. Fixed-dose combination lercanidipine/ enalapril. Drugs 2007;67(1):95-106
34. Puig JG, Calvo C, Luurila O, et al. Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM. J Hum Hypertens 2007;21(12):917-924 (Pubitemid 350162700)
35. Robles NR, Ocon J, Gomez CF, et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail 2005;1:73-80 (Pubitemid 40180111)